Akebia Therapeutics secured $41 million in a Series C funding round led by Satter Investment Management. Proceeds will go toward the development of the firm's AKB-6548, a drug candidate for anemia and cancer.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan